GSK Out-Licenses Liver Disease Drug Linerixibat to Alfasigma for Up to $690M
GSK sits 68% above its 52-week low of $32.38.
Summary
GSK has entered a licensing agreement with Alfasigma for the worldwide rights to linerixibat, an investigational drug for cholestatic pruritus in PBC, receiving an upfront payment of $300 million and potential milestones up to $390 million.
Key Events · M&A and Partnerships · GSK
-
Licensing Agreement for Linerixibat
GSK granted Alfasigma worldwide exclusive rights to develop, manufacture, and commercialize linerixibat, an investigational drug for cholestatic pruritus in primary biliary cholangitis (PBC).
-
Significant Financial Terms
GSK will receive an upfront payment of $300 million, an additional $100 million upon US FDA approval, $20 million upon EU and UK approval, and up to $270 million in sales-based milestone payments, plus tiered double-digit royalties on net sales worldwide.
-
Strategic Portfolio Focus
This agreement allows GSK to sharpen its focus on its next wave of liver disease innovation, including potential treatments for chronic hepatitis B, MASH, and ALD.
-
Advanced Regulatory Status
Linerixibat has Orphan Drug Designation in the US, EU, and Japan, and priority review in China, with marketing applications currently under regulatory review in multiple regions based on positive Phase III trial data.
Analysis · GSK · Life Sciences
This agreement allows GSK to divest a late-stage asset with positive Phase III data and regulatory applications under review, while securing significant non-dilutive capital. The deal, valued at up to $690 million including milestones, enables GSK to sharpen its focus on other promising liver disease innovations in its pipeline, such as treatments for chronic hepatitis B, MASH, and ALD. For Alfasigma, it strengthens their specialty care and rare disease portfolio, particularly in liver diseases.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.6% of the 1872 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $54.25 on NYSE in the Life Sciences sector, with a market capitalization of approximately $109.5B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.